

	Drug Name	Warhead	Mechanism of Action	Target	Number of Trials	Company
1	AGS-15E	MMAE	Tubulin polymerase inhibitor	SLITRK6	1	Astellas
2	AGS-16C3F	MMAF	Tubulin polymerase inhibitor	ENPP3 (AGS-16)	2	Astellas
3	AGS-22M6E	MMAE	Tubulin polymerase inhibitor	Nectin-4	1	Astellas
4	AMG-172	DM1	Tubulin depolymerization	CD27 (CD70L)	1	Amgen
5	AMG-595	DM1	Tubulin depolymerization	EGFRvIII	1	Amgen
6	ASG-5ME	MMAE	Tubulin polymerase inhibitor	SLC44A4 (ASG-5/SLITR6)	2	Astellas
7	BAY-79-4620	MMAE	Tubulin polymerase inhibitor	CAIX	2	Bayer
8	BAY-94-9343	DM4	Tubulin depolymerization	Mesothelin	1	Bayer
9	BIIB-015	DM4	Tubulin depolymerization	Cripto	1	Biogen
10	Brentuximab vedotin (SGN-35)	MMAE	Tubulin polymerase inhibitor	CD30	47	Takeda & Seattle Genetics
12	DEDN-6526A	MMAE	Tubulin polymerase inhibitor	Undisclosed	1	Roche
13	DMUC-5754A (RG-7458)	MMAE	Tubulin polymerase inhibitor	MUC16	1	Roche
14	Gemtuzumab ozogamicin	Calicheamicin	DNA cleavage	CD33	62	Pfizer
15	Glembatumumab vedotin	MMAE	Tubulin polymerase inhibitor	GPNMB	4	Celldex/CuraGen
38	GSK2857916	MMAF	Tubulin polymerase inhibitor	BCMA	1	GSK
16	hRS7-SN-38 (IMMU-132)	SN-38	DNA double strand break	Trop-2	1	Immunomedics
17	HuMax-TF	MMAE	Tubulin polymerase inhibitor	Tissue Factor (TF)	1	Genmab
18	IMGN-242	DM4	Tubulin depolymerization	CanAg	2	ImmunoGen
19	IMGN-289	DM1	Tubulin depolymerization	EGFR	1	ImmunoGen
20	IMGN-388	DM4	Tubulin depolymerization	α -integrin	1	ImmunoGen
21	IMGN-529	DM1	Tubulin depolymerization	CD37	1	ImmunoGen
22	IMGN-633	DM4	Tubulin depolymerization	CD33	1	ImmunoGen/Sanofi
23	IMGN-853	DM4	Tubulin depolymerization	Folate Receptor (FR α /FOLR1)	1	ImmunoGen
11	Indatuximab Ravtansine (BT-062)	DM4	Tubulin depolymerization	CD138	3	Biotest
24	Inotuzumab ozogamicin (CMC-544)	Calicheamicin	DNA cleavage	CD22	17	Pfizer
25	labetuzumab-SN-38 (IMMU-130)	SN-38	DNA double strand break	CEACAM5 (CD66e)	3	Immunomedics
26	Lorvotuzumab mertansine (IMGN-901)	DM1	Tubulin depolymerization	CD56	5	ImmunoGen
27	MDX-1203	Duocarmycin	DNA minor groove alkylation	CD70	1	BMS
28	MEDI-547	MMAF	Tubulin polymerase inhibitor	EphA2	1	MedImmune
29	Milatuzumab-doxorubicin (hLL1-DOX)	Doxorubicin	DNA intercalator	CD74	2	Immunomedics
30	MLN-0264	MMAE	Tubulin polymerase inhibitor	GCC	1	Takeda/Millennium
31	MLN-2704	DM1	Tubulin depolymerization	PSMA	2	Takeda/Millennium
32	PF-06263507	MMAF	Tubulin polymerase inhibitor	5T4	1	Pfizer
33	Pinatuzumab vedotin	MMAE	Tubulin polymerase inhibitor	CD22	1.5*	Roche
34	Polatuzumab vedotin	MMAE	Tubulin polymerase inhibitor	CD79b	2.5*	Roche
35	PSMA ADC	MMAE	Tubulin polymerase inhibitor	PSMA	5	Progenics
36	RG-7450	MMAE	Tubulin polymerase inhibitor	STEAP1	1	Roche
37	RG-7599	MMAE	Tubulin polymerase inhibitor	NaPi2b	3	Roche
39	SAR-3419	DM4	Tubulin depolymerization	CD19	5	Sanofi
40	SAR-566658	DM4	Tubulin depolymerization	huDS6 (Mucin 1)	1	Sanofi
41	SC16LD6.5	D6.5	Undisclosed	SC-16	1	Stem CentRx
42	SGN-15	Doxorubicin	DNA intercalator	Lewis Y (Le(y)) antigen	5	Seattle Genetics
43	SGN-19A	MMAF	Tubulin polymerase inhibitor	CD19	2	Seattle Genetics
44	SGN-CD33A	PBD	DNA minor groove cross-linker	CD33	1	Seattle Genetics
45	SGN-LIV1A	MMAE	Tubulin polymerase inhibitor	LIV1 (ZIP6)	1	Seattle Genetics
46	Trastuzumab emtansine (T-DM1)	DM1	Tubulin depolymerization	HER2	34	Roche
47	Vorsetuzumab mafodotin	MMAF	Tubulin polymerase inhibitor	CD70	2	Seattle Genetics

Table 5: ADCs Undergoing Clinical Trials **MMAE**: Monomethyl Auristatin E; **MMAF**: Monomethyl Auristatin F; **DM1**: Maytansinoid DM1; **DM4**: Maytansinoid DM4; **SN-38**: Topoisomerase-I inhibitor/ Irinotecan metabolite; **PBD**: Pyrrolobenzodiazepine. **GSK**: GlaxoSmithKline; **BMS**: Bristol-Myers Squibb. ADCs tested in exclusively solid tumors are highlighted in blue (n=31) and drugs tested exclusively in hematologic malignancies are highlighted in red (n=11). The ADCs highlighted in purple (n=5) are tested in both HMs and STs. *Clinical trial where both *pinatuzumab vedotin* and *polatuzumab vedotin* are tested concurrently; therefore, the 0.5 denoted in the 'Number of Trials' denotes this trial design.